According to filings with the U.S. Securities and Exchange Commission, Triomics has raised $22 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Battery Ventures, Nexus Venture Partners, Lightspeed and Y Combinator,Oncology Ventures ,and Precision Health Informatics

About Triomics
Triomics is an oncology AI company building the infrastructure that turns complex, longitudinal cancer records into structured, explainable intelligence. The company’s platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction, helping care teams, research teams, and health systems act faster on the information already in the chart. Headquartered in New York, Triomics is backed by Battery Ventures, Lightspeed, Nexus Venture Partners, Y Combinator and Oncology Ventures.

To learn more, visit https://triomics.com/
Linkedin: https://www.linkedin.com/company/triomics/

Contact:
Sarim Khan, Chief Executive Officer
https://www.linkedin.com/in/sarim-khan-triomics/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.